[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Simon Jäger\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100603495","digital-assessment-of-real-world-walking-activity-in-pulmonary-hypertension-a-prospective-multicenter-trial-100603495",false,"NCT07137260","Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial","Inclusion Criteria:\n\n* Pulmonary hypertension confirmed by right heart catheterization\n* Presence of precapillary pulmonary hypertension at time of recruitment, defined as mean pulmonary arterial pressure (MAP) ≥ 20 mmHg, pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg and pulmonary vascular resistance (PVR) \\> 2 Wood units (160 dyn·s·cm-5)\n* After the right heart catheterization another follow-up visit is required in 3, 6, or 12 months\n* Independent walking without assistance and a 6-min walking distance \\> 100m\n* WHO Functional Class I-III\n* Ability to provide informed consent and to participate in the study procedures\n* Willingness to wear the Axivity AX6 Sensor for 7 days\n\nExclusion Criteria:\n\n* Hospitalization for a pulmonological disease within the 30 days prior to study recruitment\n* Neurological or orthopedic disease which limits walking ability\n* Acute pain which limits walking ability\n* Poor vision, which limits walking ability\n* Terminal illness with life expectancy \\\u003C 1 year\n* Ongoing treatment for malignancy\n* Acute psychosis or other severe psychiatric illness\n* Substance dependence","ALL","18 Years",{"count":18,"type":19},77,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to validate digital mobility outcomes for monitoring the treatment and disease progression in adult patients with pulmonary hypertension. The main question it aims to answer is:\n\n-Do digital mobility outcomes (measured digital endpoints characterizing walking behavior) correlate with measures of precapillary pulmonary pressure as assessed by right heart catheterization?\n\nParticipants will be asked to wear a small sensor on the lower back for one week at a time for a total of 3 times: at diagnosis and follow-up visits at 3-6 months and again at 6-12 months. Follow-up visits are scheduled by the treating clinician. At the end of the study participants can choose to receive feedback on the sensor measurements.",[23,24,25,26],"Pulmonary Hypertension","Precapillary Pulmonary Hypertension","Right Heart Catheterisation","Digital Mobility Outcomes",[28,29,30,31,32,33,34,35,36,37,38,39],"Digital mobility assessment","Right heart catheterization","Mobility assessment","Digital mobility outcome","Pulmonary hypertension","Pulmonary arterial hypertension","Sensor","Axivity sensor","Precapillary pulmonary hypertension","Walking assessment","Walking test","Physical activity","RECRUITING","2025-08-15",{"date":43,"type":44},"2025-08-22","ACTUAL",{"date":46,"type":44},"2024-04-19",{"date":48,"type":19},"2027-04",{"name":50,"class":51},"Simon Jäger","OTHER",4,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":60,"enrollmentInfo":61,"targetDuration":63,"studyType":20,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100587521","cisplatin-induced-cochlear-and-vestibular-damage-in-head-and-neck-cancer-100587521","NCT06929468","Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer","Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Squamous Cell Carcinoma: A Cohort Study","Inclusion Criteria:\n\n* Diagnosis of head and neck squamous cell carcinoma\n* Cisplatin-based chemoradiotherapy (monotherapy or combination-therapy, adjuvant or neo-adjuvant) or only radiotherapy (control group)\n* Age 18 to 85 years\n* Signed agreement and willingness to participate in the study and adhere to the study protocol\n\nExclusion Criteria:\n\n* Severe hearing impairment (WHO grade 3 or 4, corresponding to an audiometric ISO value of ≥61 dB in the better ear at frequencies of 500, 1000, 2000 and 4000 Hz)\n* Self-reported tinnitus or vestibular dysfunction in the last 3 months (only lead to exclusion of the corresponding secondary objectives, not to complete exclusion from the study)\n* Current cochlear implant\n* Concurrent treatment with loop diuretics (e.g. furosemide), aminoglycoside antibiotics or other known ototoxic substances in the last three months\n* Acute psychosis or serious psychiatric illness\n* Addiction disorder","85 Years",{"count":62,"type":19},55,"6 Months","The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.",[66,67,68,69,70,71,72,73,74,75,76],"Ototoxic Hearing Loss","Ototoxicity, Drug-Induced","Cisplatin-induced Hearing Loss","Cisplatin Ototoxicity","Head and Neck Cancer","Dizzyness","Inner Ear Hearing Loss","Vestibular Disease","Squamous Cell Carcinoma of the Head and Neck","Deafness","Hearing Loss","NOT_YET_RECRUITING","2025-04-14",{"date":80,"type":44},"2025-04-16",{"date":82,"type":19},"2025-07",{"date":84,"type":19},"2027-06",{"name":50,"class":51},1,""]